Critical Analysis: Nyxoah (NASDAQ:NYXH) & Standard BioTools (NASDAQ:LAB)

Standard BioTools (NASDAQ:LAB) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Profitability

This table compares Standard BioTools and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Nyxoah	-543.21%	-163.73%	-80.24%

Valuation and Earnings

This table compares Standard BioTools and Nyxoah”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33 million	4.18	-$74.90 million	$0.20	4.56
Nyxoah	$11.33 million	5.88	-$101.92 million	($2.48)	-0.69

Standard BioTools has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Standard BioTools has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Standard BioTools and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1	2	0	0	1.67
Nyxoah	1	1	2	0	2.25

Standard BioTools currently has a consensus price target of $1.35, indicating a potential upside of 47.88%. Nyxoah has a consensus price target of $7.00, indicating a potential upside of 306.98%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts plainly believe Nyxoah is more favorable than Standard BioTools.

Insider & Institutional Ownership

53.7% of Standard BioTools shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Standard BioTools beats Nyxoah on 9 of the 14 factors compared between the two stocks.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.